China Biologic Products to Present at CCG IR's China Rising Conference and Oppenheimer's China Dragon Call Conference in New Yor
May 15 2009 - 8:00AM
PR Newswire (US)
TAIAN CITY, Shandong, China, May 15 /PRNewswire-Asia-FirstCall/ --
China Biologic Products, Inc. (OTC:CBPO) (BULLETIN BOARD: CBPO)
('China Biologic' or the 'Company'), one of the leading
plasma-based pharmaceutical companies in the People's Republic of
China ('PRC'), today announced that the Company's management will
present at the upcoming China Rising Conference hosted by CCG
Investor Relations in New York, NY on May 18, 2009 and the 3rd
Annual China Dragon Call Conference hosted by Oppenheimer & Co.
Inc. on May 19 to 21, 2009. The date, time and location of China
Biologic' presentation at the China Rising Conference is as
follows: Date: Monday, May 18, 2009 Time: 10:30 a.m. to 11:00 a.m.
Eastern Time Presenter: Tristan Kuo, Chief Financial Officer of
China Biologic Venue: The Yale Club 50 Vanderbilt Avenue New York,
NY 10017 Webcast: http://www.chinarisingconference.com/webcast.html
A replay of the webcast will be available for up to one year
following the presentation using the same link. The China Rising
Investment Conference hosted by CCG Investor Relations will provide
over 250 fund managers and investors access to senior management of
a wide range of Chinese growth companies in sectors including
consumer staples, agriculture, pharmaceuticals, infrastructure,
information technology, advanced materials, capital goods, and
alternative energy. The conference will include over 30 US-listed
Chinese companies and a number of private companies. Interested
parties and investors may find more information for the conference
by visiting the website at http://www.chinarisingconference.com/ .
The date, time and location of China Biologic's presentation at the
Oppenheimer 3rd Annual China Dragon Call Conference are as follows:
Date: Tuesday, May 19, 2009 Time: 10:15 p.m. to 10:45 p.m. Eastern
Time Presenter: Tristan Kuo, Chief Financial Officer of China
Biologic Venue: 300 Madison Avenue New York City The China Dragon
Call Conference hosted by Oppenheimer & Co. Inc. will provide
intimate access to senior management of leading Chinese companies.
These discussions will give investors an ability to analyze secular
trends, to identify emerging opportunities and to gather insight
into China's investment outlook. All conferences are for
institutional clients of Oppenheimer & Co. Inc. and are by
invitation only. For more information, please contact Oppenheimer
& Co. Inc. institutional sales representative. About China
Biologic Products, Inc. China Biologic Products, Inc. (the
'Company'), through its indirect majority-owned subsidiary,
Shandong Taibang Biological Products Co. Ltd., and equity
investments in Xi'an Huitian Blood Products Co., Ltd. and Chongqing
Dalin Biologic Technologies Co., Ltd. is currently the largest
non-state-owned plasma-based biopharmaceutical company approved by
the Chinese government. The Company is a fully integrated biologic
products company with plasma collection, production and
manufacturing, research and development, and commercial operations.
The Company's blood products are irreplaceable in the application
of medical emergencies, and prevention and treatment for various
diseases. It sells its plasma-based biopharmaceutical products to
hospitals and other healthcare facilities in China. Safe Harbor
Statement This release may contain certain 'forward-looking
statements" relating to the business of China Biologic Products,
Inc. and its subsidiary companies. All statements, other than
statements of historical fact included herein are 'forward-looking
statements," including statements regarding: the ability of the
Company to achieve its commercial objectives; the business
strategy, plans and objectives of the Company and its subsidiaries;
and any other statements of non-historical information. These
forward-looking statements are often identified by the use of
forward-looking terminology such as "believes," 'expects' or
similar expressions, involve known and unknown risks and
uncertainties. Although the Company believes that the expectations
reflected in these forward-looking statements are reasonable, they
do involve assumptions, risks and uncertainties, and these
expectations may prove to be incorrect. Investors should not place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. The Company's actual
results could differ materially from those anticipated in these
forward-looking statements as a result of a variety of factors,
including those discussed in the Company's periodic reports that
are filed with the Securities and Exchange Commission and available
on its website (http://www.sec.gov/). All forward-looking
statements attributable to the Company or persons acting on its
behalf are expressly qualified in their entirety by these factors.
Other than as required under the securities laws, the Company does
not assume a duty to update these forward-looking statements. For
more information, please contact: Company Contact: Mr. Y. Tristan
Kuo Chief Financial Officer China Biologic Products, Inc. Tel:
+86-538-6202206 Email: Web: http://www.chinabiologic.com/ Investor
Relations Contact: Mr. Crocker Coulson, President CCG Investor
Relations Tel: +1-646-213-1915 (NY office) or Mr. Gary Chin Tel:
+1-646-213-1909 Email: Web: http://www.ccgirasia.com/ DATASOURCE:
China Biologic Products, Inc. CONTACT: Y. Tristan Kuo, Chief
Financial Officer at China Biologic Products, Inc. at
+86-538-6202206 or ; Investor Relations Contact: Crocker Coulson,
President, CCG Investor Relations at +1-646-213-1915 (NY office) or
or Gary Chin at +1-646-213-1909 Web site:
http://www.chinabiologic.com/
http://www.chinarisingconference.com/webcast.html
Copyright